Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection - excipient ingredients: water for injections - vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (nsclc). in patients with stage iv nsclc, vinorelbine is indicated as a single agent or in combination with cisplatin. in stage iii nsclc, vinorelbine is indicated with in combination with cisplatin.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (nsclc), as a single agent or in combination. vinorelbine tartrate is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. in addition, vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - vinorelbine tartrate, quantity: 69.25 mg (equivalent: vinorelbine, qty 50 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - vinorelbine tartrate, quantity: 13.85 mg (equivalent: vinorelbine, qty 10 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - vinorelbine tartrate, quantity: 69.25 mg (equivalent: vinorelbine, qty 50 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg (equivalent: vinorelbine, qty 10 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. vinorelbine pierre fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. vinorelbine pierre fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (nsclc), as a single agent or in combination. it is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. in addition vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

United States - English - NLM (National Library of Medicine)

pierre fabre pharmaceuticals, inc. - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine 10 mg in 1 ml - navelbine is a vinca alkaloid indicated: - in combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) - as a single agent, for the treatment of patients with metastatic nsclc none risk summary based on findings from animal studies and its mechanism of action [see clinical pharmacology (12.1))] , navelbine can cause fetal harm when administered to a pregnant woman. available human data are insufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively ( see data ). advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies ar